Aimmune begins second Phase III of AR101 for peanut allergy

Aimmune Therapeutics Inc. (NASDAQ:AIMT) began the Phase III RAMSES trial to evaluate escalating doses of oral AR101 for about 6 months to treat peanut allergy. The double-blind, placebo-controlled, North American trial will enroll about 440 patients ages 4-17 and evaluate safety as its primary endpoint. After the 6-month, blinded period, patients will receive maintenance treatment with 300 mg AR101 daily for ≥6 months...